Nissen SE, Lincoff AM, Wolski K, et al. - Adverse cardiovascular outcomes can not be reduced by pharmacologically achieving higher eicosapentaenoic acid (EPA) plasma levels, and higher docosahexaenoic acid (DHA) levels do not confer any harm.

• A secondary analysis of a randomized clinical trial (STRENGTH Trial).

• Patients at high cardiovascular risk were randomized to receive 4 g daily of ω-3 carboxylic acid (CA) or an inert comparator, corn oil.

• In the ω-3 CA group, median plasma levels at 12 months were 89 μg/mL and 91 μg/mL for EPA and for DHA, respectively.

• Highest achieved tertials of EPA and DHA in the ω-3 CA group were related to neither benefit nor harm.